Jiao Yingwei, Liu Qiang, Zhao Hongbo, Hu Xianzhen, Sun Jinlong, Liu Xiaohong
Department of Proctology, Shaanxi Nuclear Industry 215 Hospital, Xianyang, Shaanxi 712000, China.
Four Departments of General Surgery, Shaanxi Nuclear Industry 215 Hospital, Xianyang, Shaanxi 712000, China.
Evid Based Complement Alternat Med. 2021 Sep 18;2021:1858974. doi: 10.1155/2021/1858974. eCollection 2021.
Colon cancer (CC) shows a gradual increasing incidence in recent years, and chemotherapy is a frequently adopted treatment for patients with middle or advanced colon cancer (ACC), but it lacks prognostic markers after CC.
The changes of lncRNA CASC9 in 58 patients with CC were determined using a real-time quantitative PCR (qRT-PCR) assay before and after chemotherapy, and the correlation of serum lncRNA CASC9 with efficacy of FOLFOX4 regimen (oxaliplatin + calcium folinate + fluorouracil) was analyzed. The patients were followed up to understand the association of lncRNA CASC9 with overall survival (OS) and progression-free survival (PFS).
Patients with CC showed notably higher lncRNA CASC9 expression than controls, and lncRNA CASC9 presented an association with the clinical stage of the patients. In addition, lncRNA CASC9 demonstrated a clinical value in predicting efficacy on patients and acted as one independent prognostic factor for PFS in patients with ACC.
With increased expression of serum lncRNA CASC9, patients with ACC suffered an unfavorable chemotherapy effect. In addition, serum lncRNA CASC9 is a promising sensitive indicator for prediction of ACC and is related to the clinical efficacy and prognosis of patients.
近年来结肠癌（CC）的发病率呈逐渐上升趋势，化疗是中晚期结肠癌（ACC）患者常用的治疗方法，但CC后缺乏预后标志物。
采用实时定量PCR（qRT-PCR）检测58例CC患者化疗前后lncRNA CASC9的变化，并分析血清lncRNA CASC9与FOLFOX4方案（奥沙利铂+亚叶酸钙+氟尿嘧啶）疗效的相关性。对患者进行随访，了解lncRNA CASC9与总生存期（OS）和无进展生存期（PFS）的关系。
CC患者lncRNA CASC9表达明显高于对照组，且lncRNA CASC9与患者临床分期相关。此外，lncRNA CASC9在预测患者疗效方面具有临床价值，是ACC患者PFS的独立预后因素之一。
血清lncRNA CASC9表达升高，ACC患者化疗效果不佳。此外，血清lncRNA CASC9是一种有前景的预测ACC的敏感指标，与患者的临床疗效和预后相关。
